Chronic myelomonocytic leukemia (CMML) is an aggressive hematological malignancy characterized by sustained peripheral blood monocytosis and an inherent risk for leukemic blast transformation^[@CR1],[@CR2]^. Patients with CMML have between 10--15 mutations per kilobase of coding DNA regions; with majority of these (\>90%) involving epigenetic regulator genes (*TET2* 60%, *ASXL1* 40%), splicing machinery (*SRSF2* 40%), and cell signaling (oncogenic *RAS* pathway 30%)^[@CR3]--[@CR5]^. The polycomb group proteins play an important role in transcriptional repression by regulating chromatin modifications and consist of two canonical polycomb repressive complexes (PRC) PRC1 and PRC2^[@CR6]^. PRC2, comprises EED (embryonic ectoderm development protein), EZH2 (enhancer of zeste homolog 2), SUZ12 (suppressor of zeste 12 protein homolog), and RBBP4/7 (retinoblastoma binding protein), is recruited to chromatin and results in the trimethylation of lysine 27 of the histone 3 mark (H3K27me3), a repressive mark silencing gene transcription. In addition, *ASXL1* (additional sex combs like 1) has been shown to associate with PRC2 and results in global reductions in H3K27me3, suggesting a regulatory role in the PRC2^[@CR7]^.

*ASXL1* mutations (frameshift and nonsense) result in the truncation of the ASXL1 protein, are seen in \~40% of CMML patients, and independently and adversely impact overall survival (OS)^[@CR4],[@CR8]^. *EZH2* mutations (chromosome 7q36.1) in CMML, unlike in epithelial malignancies and lymphoproliferative disorders, are loss-of-function mutations and are uncommon (\<5%), with an indeterminate prognostic impact^[@CR4],[@CR9]^. Given that the co-occurrence of these mutations have been documented in myeloid neoplasms and that theoretically these could further impact the repressive role of the PRC2, we examined a large and informative CMML data set to assess the prognostic impact of *ASXL1* and *EZH2* co-mutations in CMML^[@CR10]^.

Patients with 2016 WHO (World Health Organization)-defined CMML were identified from the institutional database^[@CR1]^. Al.(BM) biopsies and cytogenetic studies performed at diagnosis. A 29 gene panel next-generation sequencing assay was carried out on BM DNA specimens on all 277 patients obtained at diagnosis for the following genes: *TET2*,*DNMT3A*,*IDH1*,*IDH2*, *ASXL1*,*EZH2*,*SUZ12*, *SRSF2*,*SF3B1*,*ZRSR2*,*U2AF1,* *PTPN11*,*Tp53*,*SH2B3*,*RUNX1*,*CBL*,*NRAS*,*KRAS*,*JAK2*,*CSF3R*,*FLT3*,*KIT*,*CALR*,*MPL,* *NPM1*,*CEBPA*,*IKZF*,*ETNK1*, and *SETBP1*, by previously described methods^[@CR5],[@CR9]^. All statistical analyses considered parameters obtained at time of CMML diagnosis. Differences in the distribution of continuous variables between categories were analyzed by either Mann--Whitney or Kruskal--Wallis tests. Patient groups with nominal variables were compared by *χ*^2^ test. OS was calculated from the date of first referral to date of death or last contact. Leukemia-free survival (LFS) was calculated from the date of first referral to date of leukemic transformation or death/last contact. Overall and LFS curves were prepared by the Kaplan--Meier method and compared by the log-rank test. Cox proportional hazard regression model was used for multivariable analysis.

Two hundred and seventy-seven WHO-defined CMML patients were included in the study; median age 72 years (range, 18--92), 66% males. *ASXL1* mutations were identified in 138 (50%) patients, whereas *EZH2* mutations were identified in 7 (3%) patients; all 7 (100%) being co-mutated for *ASXL1* (Table [1](#Tab1){ref-type="table"}). *EZH2* mutation types included; missense 3 (43%), nonsense 2 (28%), and 1 (14%) each for frameshift mutations and intronic mutations impacting splicing (splice site mutation). Four (57%) patients with *EZH2* mutations had a proliferative CMML phenotype, while three (43%) patients had an abnormal karyotype, including trisomy 8, isochromosome 17q, and a balanced translocation---*t*(3;12;6)(p21;q21;q23), respectively. Mutational frequencies in the *ASXL1/EZH2* co-mutated cohort included *TET2* 57%, *RUNX1* 43%, *SRSF2* 29%, and 14% each for *JAK2*V617F, *FLT3*-ITD, *BCOR, CBL, NRAS*, and *SETBP1*. Notably there were no mutations involving *DNMT3A*,*IDH1*,*IDH2*,*SF3B1*,*U2AF1*,*ZRSR2*, or *TP53*. In comparison to *ASXL1*mut/*EZH2*wt and *ASXL1*wt/*EZH2*wt, patients with *ASXL1/EZH2* co-mutations were more likely to have additional mutations involving *RUNX1* (43%, *p* = 0.001), *BCOR* (14%, *p* \< 0.0001), *FLT3*-ITD (14%, *p* = 0.04) and less likely to have *SF3B1* mutations (0%, *p* = 0.003). The *ASXL1/EZH2* co-mutated patients were also more likely to have higher risk stratification by the *ASXL1* integrated Mayo Molecular Model (*p* \< 0.0001) and the GFM CMML prognostic model (*p* \< 0.0001).Table 1Clinical and laboratory characteristics of 277 CMML patients stratified by their *ASXL1* and *EZH2* mutational statusVariablesAll patients with CMML (*n *= 277)*ASXL1mt/EZH2mt* CMML patients (*n *= 7, 3%)*ASXL1mt* CMML patients (*n *= 131, 47%)*ASXL1wt* CMML patients (*n *= 139, 50%)*P*-value comparing *ASXL1mt/EZH2mt* patients with *ASXL1m*t and *ASXL1wt*Age in years; median (range)72.3 (18--92)67 (65--79)72.5 (27--92)72.4 (18--92)0.7Males; *n* (%)183 (66)6 (86)89 (68)88 (63)0.4Hemoglobin, g/dL; median (range)10.7 (6.4--17)11.3 (7.2--15)10.7 (6.4--16.8)10.9 (7.1--17)0.7WBC × 10^9^/L; median (range)12.3 (2--265)14.1 (6--51)14.3 (2--265)10 (2--186)**0.01**ANC × 10^9^/L; median (range)6.2 (0.1--1516.3 (3.2--32)7.6 (0.2--151)5.2 (0.1--143)**0.04**AMC × 10^9^/L; median (range)2.5 (1--40)2.8 (1--8)3 (1--40)2 (1--30)**0.007**ALC × 10^9^/L; median (range)1.7 (0--22)1.6 (1.2--6)1.9 (0.4--22)1.6 (0--11)0.13Platelets × 10^9^/L; median (range)98 (10--840)211 (25--526)95 (10--726)100 (12--840)0.1Presence of circulating immature myeloid cells; *n* (%)156 (56)5 (71)81 (62)70 (50)0.09PB blast %; median (range)0 (0--19)0 (0--4)0 (0--19)0 (0--12)0.6BM blast %; median (range)3 (0--19)1 (0--10)4 (0--19)3 (0--18)0.08Lactate dehydrogenase levels IU/ml; median (range)226 (84--1296)271 (163--604)243 (84--1296)215 (131--719)0.1Cytogenetics(*n*=267)(*n*=124)(*n*=136)0.7abnormal; *n* (%)85 (32)3 (43)41 (33)41 (30)FAB CMML classification(*n*=276)(*n*=138)**0.005** Proliferative135 (49)4 (57)77 (59)54 (39) Dysplastic141 (51)3 (43)54 (41)84 (61)Therapy-related CMML; *n* (%)28 (101 (14)11 (8)16 (12)0.7Next-generation sequencing analysis; *n* (%)1. Epigenetic regulators* TET2*154 (56)4 (57)59 (45)91 (65)**0.003*** DNMT3A*16 (6)07 (5)9 (6)0.7* IDH1*5 (2)03 (2)2 (1)0.8* IDH2*16 (6)08 (6)8 (6)0.82. Transcription factors* RUNX1*21 (8)3 (43)11 (8)7 (5)**0.001*** BCOR*1 (0.5)1 (14)00**\<0.0001**3. Spliceosome components* SF3B1*15 (5)01 (1)14 (10)**0.003*** SRSF2*129 (47)2 (29)63 (48)64 (46)0.6* U2AF1*19 (7)012 (9)7 (5)0.3* ZRSR2*8 (3)02 (2)6 (4)0.44. Cell signaling* JAK2 V617F*20 (7)1 (14)9 (7)10 (7)0.8* MPL*2 (1)002 (1)0.4* SH2B3*1 (0.5)01 (1)00.6* CBL*37 (13)020 (15)17 (12)0.4* NRAS*44 (16)1 (14)25 (19)18 (13)0.4* KRAS*12 (4)1 (14)8 (6)3 (2)0.1* PTPN11*8 (3)05 (4)3 (2)0.6* CSF3R*4 (1)02 (2)2 (1)0.9* C-KIT*8 (3)04 (3)4 (3)0.9* FLT3*7 (3)1 (14)1 (1)5 (4)**0.04*** NPM1*1 (0.5)001 (1)0.6* CALR*1 (0.5)001 (1)0.65. Tumor suppressor genes* Tp53*7 (3)01 (1)6 (4)0.26. Others* SETBP1*37 (13)1 (14)26 (20)10 (7)**0.009*** CEBPA*3 (1)01 (1)2 (1)0.82016 WHO morphological subtypes; *n* (%)(*n*=275)(*n*=129)0.9 CMML-0155 (56)5 (71)73 (57)77 (55) CMML-170 (25)1 (14)31 (24)38 (27) CMML-250 (18)1 (14)25 (19)24 (17)Spanish cytogenetic risk stratification; *n* (%)(*n*=270)(*n*=126)(*n*=137)0.5 Low202 (75)4 (57)90 (71)108 (79) Intermediate42 (16)2 (29)22 (17)18 (13) High26 (10)1 (14)14 (11)11 (18)Mayo-French cytogenetic risk stratification; *n* (%)(*n*=270)(*n*=126)(*n*=137)0.2 Low201 (74)4 (57)89 (71)108 (79) Intermediate55 (20)2 (29)32 (25)21 (15) High14 (5)1 (14)5 (4)8 (6)Mayo prognostic model; *n* (%)(*n*=274)(*n*=129)(*n*=138)0.14 Low86 (31)035 (27)51 (37) Intermediate88 (32)4 (57)45 (35)39 (28) High100 (36)3 (43)49 (38)48 (35)Molecular Mayo model; *n* (%)(*n*=260)(*n*=126)(*n*=127)**\<0.0001** Low20 (8)0020 (16) Intermediate-167 (26)019 (15)48 (38) Intermediate-283 (32)4 (57)37 (29)42 (33) High90 (35)3 (43)70 (56)17 (13)GFM CMML prognostic model; *n* (%)(*n*=268)(*n*=129)(*n*=132)**\<0.0001** Low117 (44)1 (14)29 (22)87 (66) Intermediate100 (37)4 (57)59 (46)37 (28) High51 (19)2 (29)41 (32)8 (6)Leukemic transformation; *n* (%)48 (17)027 (21)21 (15)0.23Deaths; *n* (%)169 (61)3 (43)87 (66)79 (57)0.2Follow-up in months; median (range)16 (0.03--194)6 (0.2--24)0.07-15 (0.07--183)19 (0.03--194)0.08The bold values represent statistically significant *p* values, *p* \< 0.05*mt* mutant, *wt* wild type, *WBC* white blood cell count, *ANC* absolute neutrophil count, *AMC* absolute monocyte count, *ALC* absolute lymphocyte count, *PB* peripheral blood, *BM* bone marrow, *WHO* World Health Organization, *GFM*Groupe Francophone des Myélodysplasies, *FAB*French--American--British, *BT* blast transformation

At last follow-up (median, 16 months), 169 (61%) deaths and 48 (17%) leukemic transformations were documented. Median survival for *ASXL1/EZH2* co-mutated patients was 16 months, in comparison to 20 months for *ASXL1*mt/*EZH2*wt and 33 months for *ASXL1*wt/*EZH2*wt patients (*p* \< 0.0001, Fig. [1](#Fig1){ref-type="fig"}). In a univariate analysis, survival (OS) was adversely impacted by male sex (*p* = 0.03), low hemoglobin (HB \< 10 gm/dl, *p* = 0.001), high white blood cell count (WBC \> 15 × 10(9)/L; *p* = 0.0003), high absolute monocyte count (AMC \> 10 × 10(9)/L, *p* = 0.0002), high absolute lymphocyte count (*p* = 0.02), presence of circulating immature myeloid cells (IMC, *p* = 0.002), peripheral blood (*p* = 0.001) and BM (*p* = 0.045) blast %, abnormal karyotype (*p* = 0.0008), absence of *TET2* mutations (*p* = 0.0003), presence of *ASXL1* (*p* = 0.009), *DNMT3A* (*p* = 0.001), and *Tp53* (*p* = 0.02) mutations. *EZH2* mutations by themselves did not impact OS (*p* = 0.2); however, when analyzed in the context of *ASXL1*mt/*EZH2*mt status, in comparison to *ASXL1*mutations, the adverse impact of the co-mutations was significantly stronger (*p* = 0.04, HR 2.9, 95% CI 1.1--9.5). In a multivariable survival analysis that included the aforementioned significant variables, only high WBC \> 15 × 10(9)/L (*p* = 0.005, HR 1.005, 95% CI 1.003--1.009), male sex (*p* = 0.002, HR 1.7, 95% CI 1.2--2.4), presence of IMC (*p* = 0.009, HR 1.5, 95% CI 1.1--2.4), presence of *ASXL1/EZH2* co-mutations (*p* = 0.03, HR 2.1 95% CI 1.2--3.2), presence of *DNMT3A* mutations (*p* = 0.002, HR 2.8, 95% CI 1.4--5.4), and absence of *TET2* mutations (*p* = 0.0006, HR 1.7, 95% CI 1.2--2.4) independently and adversely impacted OS. The prognostic relevance of *ASXL1/EZH2* co-mutational status was lost when assessed in context of the Mayo Molecular Model (*p* = 0.2) and the GFM CMML model (*p* = 0.4). Neither did *ASXL1* (*p* = 0.14) nor *EZH2* (*p* = 0.3) mutations impact LFS.Fig. 1Overall survival of *ASXL1*, *EZH2*, and *DNMT3A* mutational status.

In summary, our study has demonstrated that *EZH2* mutations are infrequent (\<5%) in WHO-defined CMML, almost always co-occur with *ASXL1* mutations, are not associated with *DNMT3A* or *SF3B1* mutations, and are frequently associated with a "proliferative" CMML phenotype. While *EZH2* mutations themselves did not impact either OS or LFS, *ASXL1/EZH2* co-mutated patients had higher risk stratification by the *ASXL1*-integrated CMML prognostic models and had a shorter survival, in comparison to *ASXL1mt* patients alone. Mechanistic studies, including chromatin immunoprecipitation and sequencing (ChIP-seq) are needed to see if the *ASXL1/EZH2* co-mutational status indeed synergistically impacts PRC2 activity and further depletes methylation of H3K27, resulting in unbridled transcription.
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